During the past decade, Irccs Crob conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 10 clinical trials were completed, i.e. on average, 47.6% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Irccs Crob" #1 sponsor was "Fondazione Italiana Linfomi ONLUS" with 10 trials, followed by "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 8 trials sponsored, "Celgene" with 5 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Consorzio Oncotech" with 5 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Irccs Crob" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Clinical Research Technology S.r.l." with 2 trials as a collaborator, "A.O. Ospedale Papa Giovanni XXIII" with 1 trials as a collaborator, "Agenzia Italiana del Farmaco" with 1 trials as a collaborator and "Fondazione EMN Italy Onlus" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Irccs Crob" are "Multiple Myeloma" (5 trials), "Leukemia" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials) and "Chronic Myeloid Leukemia" (2 trials). Many other conditions were trialed in "Irccs Crob" in a lesser frequency.

Most popular intervention types in "Irccs Crob" are "Drug" (45 trials), "Other" (7 trials), "Genetic" (2 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (5 trials), "Placebo" (5 trials), "Lenalidomide" (4 trials), "Rituximab" (4 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Irccs Crob" are 53 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Irccs Crob". undefined are not yet recruiting, 8 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Irccs Crob, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Irccs Crob, 1 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Irccs Crob has several departments that took part in Clinical trials: "Ospedale Oncologico Regionale; U.O. Oncologia Medica Ed Ematologia" - 3 trials